Agency notices · Notice

Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing

Record date · Nov 18, 2026

Open official record

About this record

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of new drug application (NDA) 206679 for Flolipid suspension, 20 milligrams (mg)/5 milliliters (mL) and 40 mg/5 mL and is announcing an opportunity for the NDA holder, Salerno Pharmaceuticals, 2431 East 61st St., Suite 300, Tulsa, OK 74136, to request a hearing on this proposal. The basis for the proposal is that Salerno Pharmaceuticals has repeatedly failed to file required annual reports for NDA 206679.

Record details

Federal Register document
2026-23413
Stated comment deadline
2027-01-19

Sources and related records

Source checked .